Addition of zoledronic acid to neoadjuvant chemotherapy is not beneficial in patients with HER2-negative stage II/III breast cancer: 5-year survival analysis of the NEOZOTAC trial (BOOG 2010-01)

[1]  D. Dodwell,et al.  Benefits and risks of adjuvant treatment with zoledronic acid in stage II/III breast cancer. 10 years follow-up of the AZURE randomized clinical trial (BIG 01/04) , 2018, Journal of bone oncology.

[2]  M. Mouret-Reynier,et al.  Comparative Study of Neoadjuvant Chemotherapy With and Without Zometa for Management of Locally Advanced Breast Cancer With Serum VEGF as Primary Endpoint: The NEOZOL Study , 2018, Clinical breast cancer.

[3]  M. Gnant,et al.  Adjuvant Bisphosphonate Therapy in Postmenopausal Breast Cancer , 2018, Current Treatment Options in Oncology.

[4]  T. Ishikawa,et al.  Survival outcomes of neoadjuvant chemotherapy with zoledronic acid for HER2-negative breast cancer. , 2017, The Journal of surgical research.

[5]  F. Guadagni,et al.  Pretreatment Insulin Levels as a Prognostic Factor for Breast Cancer Progression. , 2016, The oncologist.

[6]  R. Gray,et al.  Adjuvant bisphosphonates in early breast cancer: consensus guidance for clinical practice from a European Panel. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  H. Pijl,et al.  Insulin-like growth factor 1 receptor expression and IGF1R 3129G > T polymorphism are associated with response to neoadjuvant chemotherapy in breast cancer patients: results from the NEOZOTAC trial (BOOG 2010-01) , 2016, Breast Cancer Research.

[8]  H. Putter,et al.  Effects of neoadjuvant chemotherapy with or without zoledronic acid on pathological response: A meta-analysis of randomised trials , 2015, European journal of cancer.

[9]  T. Ishikawa,et al.  Randomized Controlled Trial of Zoledronic Acid plus Chemotherapy versus Chemotherapy Alone as Neoadjuvant Treatment of HER2-Negative Primary Breast Cancer (JONIE Study) , 2015, PloS one.

[10]  H. Putter,et al.  The effects of short-term fasting on tolerance to (neo) adjuvant chemotherapy in HER2-negative breast cancer patients: a randomized pilot study , 2015, BMC Cancer.

[11]  E. Rutgers,et al.  Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials , 2015, The Lancet.

[12]  P. Scherer,et al.  Hyperglycemia as a Risk Factor for Cancer Progression , 2014, Diabetes & metabolism journal.

[13]  M. Aapro,et al.  Bone health in cancer patients: ESMO Clinical Practice Guidelines. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[14]  H. Putter,et al.  Addition of zoledronic acid to neoadjuvant chemotherapy does not enhance tumor response in patients with HER2-negative stage II/III breast cancer: the NEOZOTAC trial (BOOG 2010-01). , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[15]  I. Holen,et al.  Zoledronic Acid Has Differential Antitumor Activity in the Pre- and Postmenopausal Bone Microenvironment In Vivo , 2014, Clinical Cancer Research.

[16]  C. V. D. van de Velde,et al.  Can Zoledronic Acid be Beneficial for Promoting Tumor Response in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy? , 2013, Journal of clinical medicine.

[17]  M. Kipanyula,et al.  Insulin resistance and cancer: the role of insulin and IGFs. , 2013, Endocrine-related cancer.

[18]  C. Leonetti,et al.  Evaluation of the in vitro and in vivo antiangiogenic effects of denosumab and zoledronic acid , 2012, Cancer biology & therapy.

[19]  Wei Zhu,et al.  Altered Expression of Insulin Receptor Isoforms in Breast Cancer , 2011, PloS one.

[20]  I. Holen,et al.  Tumour macrophages as potential targets of bisphosphonates , 2011, Journal of Translational Medicine.

[21]  H. Sommer,et al.  Effect of zoledronate on persisting isolated tumour cells in patients with early breast cancer. , 2010, Anticancer research.

[22]  M. Ellis,et al.  Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial. , 2010, The Lancet. Oncology.

[23]  R E Coleman,et al.  The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancer , 2010, British Journal of Cancer.

[24]  B. Clarke,et al.  Bisphosphonates: mechanism of action and role in clinical practice. , 2008, Mayo Clinic proceedings.

[25]  Mark B. Jones,et al.  Antitumor effects of doxorubicin followed by zoledronic acid in a mouse model of breast cancer. , 2008, Journal of the National Cancer Institute.

[26]  I. Holen,et al.  Exploring the anti-tumour activity of bisphosphonates in early breast cancer. , 2008, Cancer treatment reviews.

[27]  D. Bikle,et al.  Role of IGF‐I Signaling in Regulating Osteoclastogenesis , 2006, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[28]  Ivo Que,et al.  Interference with the microenvironmental support impairs the de novo formation of bone metastases in vivo. , 2005, Cancer research.

[29]  A. Hutcheon,et al.  A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival. , 2003, Breast.

[30]  G. Avvisati,et al.  Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[31]  O. Fromigué,et al.  Bisphosphonates antagonise bone growth factors' effects on human breast cancer cells survival , 2003, British Journal of Cancer.

[32]  M. Wilhelm,et al.  Stimulation of γδ T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma , 2000 .

[33]  Y. Yen,et al.  Bisphosphonates suppress insulin‐like growth factor 1‐induced angiogenesis via the HIF‐1α/VEGF signaling pathways in human breast cancer cells , 2010, International journal of cancer.

[34]  C. Agrati,et al.  In vivo effects of zoledronic acid on peripheral γδ T lymphocytes in early breast cancer patients , 2008, Cancer Immunology and Immunotherapy.

[35]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..

[36]  B. Hoffman,et al.  Fasting insulin and outcome in early-stage breast cancer: results of a prospective cohort study. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  B. Hoffman,et al.  Fasting Insulin and Outcome in Early-Stage Breast Cancer: Results of a Prospective Cohort Study , 2002 .

[38]  H. Tony,et al.  Stimulation of gammadelta T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma. , 2000, Blood.

[39]  H. Tony,et al.  Stimulation of gd T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma , 2022 .